Literature DB >> 15283951

Long-term effects of ketamine: evidence for a persisting impairment of source memory in recreational users.

Celia J A Morgan1, Marcio Riccelli, Charles H Maitland, H Valerie Curran.   

Abstract

RATIONALE: Ketamine is an N-methyl-d-aspartate (NMDA)-receptor antagonist that is increasingly being used as a recreational drug. Previous research has shown gross generalised verbal memory impairments persisting 3 days after ketamine use in chronic users, however episodic memory has not specifically investigated in this population.
OBJECTIVE: To determine whether ketamine, on the night of drug use (day 0) and 3 days later, is associated with impaired episodic memory as assessed by a source memory task.
METHODS: Twenty ketamine users and 20 poly-drug controls were compared on a source memory task both on day 0 and 3. Participants also completed questionnaires on both days indexing schizophrenic-like and dissociative symptoms.
RESULTS: On day 0, ketamine abusers were impaired on both source memory and item recognition and scored more highly on schizophrenic and dissociative symptom scales compared to poly-drug controls. On day 3 ketamine abusers only displayed source memory impairments and these positively correlated with the level of schizophrenic-like symptoms on day 0. No differences on day 3 in schizophrenic-like or dissociative symptoms were observed.
CONCLUSIONS: Ketamine abusers exhibit a persisting deficit in source memory on day 3 but not in item recognition. These findings suggest that repeated use of ketamine produces chronic impairments to episodic memory.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15283951     DOI: 10.1016/j.drugalcdep.2004.03.006

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  33 in total

Review 1.  Glutamatergic model psychoses: prediction error, learning, and inference.

Authors:  Philip R Corlett; Garry D Honey; John H Krystal; Paul C Fletcher
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

2.  Hydroxynorketamine Blocks N-Methyl-d-Aspartate Receptor Currents by Binding to Closed Receptors.

Authors:  Jamie A Abbott; Gabriela K Popescu
Journal:  Mol Pharmacol       Date:  2020-06-29       Impact factor: 4.436

Review 3.  Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.

Authors:  Marc S Lener; Bashkim Kadriu; Carlos A Zarate
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

4.  Serum brain-derived neurotrophic factor and nerve growth factor decreased in chronic ketamine abusers.

Authors:  Xiaoyin Ke; Yi Ding; Ke Xu; Hongbo He; Minling Zhang; Daping Wang; Xuefeng Deng; Xifan Zhang; Chao Zhou; Yuping Liu; Yuping Ning; Ni Fan
Journal:  Drug Alcohol Depend       Date:  2014-07-11       Impact factor: 4.492

Review 5.  Ketamine for chronic pain: risks and benefits.

Authors:  Marieke Niesters; Christian Martini; Albert Dahan
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

6.  Chronic administration of ketamine mimics the perturbed sense of body ownership associated with schizophrenia.

Authors:  Jinsong Tang; Hannah L Morgan; Yanhui Liao; Philip R Corlett; Dong Wang; Hong Li; Yanqing Tang; Jindong Chen; Tieqiao Liu; Wei Hao; Paul C Fletcher; Xiaogang Chen
Journal:  Psychopharmacology (Berl)       Date:  2014-11-19       Impact factor: 4.530

7.  Subanalgesic ketamine enhances morphine-induced antinociceptive activity without cortical dysfunction in rats.

Authors:  Hiroki Shikanai; Sachiko Hiraide; Hidekazu Kamiyama; Tsukasa Kiya; Koji Oda; Yoshikazu Goto; Yoshiki Yanagawa; Kei-ichi Shimamura; Yukiko Goda; Hiroko Togashi
Journal:  J Anesth       Date:  2013-10-11       Impact factor: 2.078

8.  Rats tested after a washout period from sub-chronic PCP administration exhibited impaired performance in the 5-Choice Continuous Performance Test (5C-CPT) when the attentional load was increased.

Authors:  Sam A Barnes; Jared W Young; Jo C Neill
Journal:  Neuropharmacology       Date:  2011-05-05       Impact factor: 5.250

9.  Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteers.

Authors:  Lawrence P Carter; Bethea A Kleykamp; Roland R Griffiths; Miriam Z Mintzer
Journal:  Psychopharmacology (Berl)       Date:  2012-10-25       Impact factor: 4.530

10.  Is persistent ketamine use a valid model of the cognitive and oculomotor deficits in schizophrenia?

Authors:  Celia J A Morgan; Vyv Huddy; Michelle Lipton; H Valerie Curran; Eileen M Joyce
Journal:  Biol Psychiatry       Date:  2008-12-25       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.